<DOC>
	<DOCNO>NCT00445419</DOCNO>
	<brief_summary>Pevion Biotech design therapeutic vaccine treat patient suffer chronic hepatitis C virus infection . The vaccine base combination PeviPRO PeviTER platform use synthetic peptide antigens hepatitis C virus . Generally , cellular immune response cytotoxic T-lymphocytes ( CTL ) seem crucial overcome hepatitis C virus infection . In-depth research recent year show cellular immune response even effective support helper T-cells . Pevion Biotech 's HCV vaccine candidate utilizes effect induce specific CTL response ( PeviTER ) together supportive helper T cell response ( PeviPRO ) . This virosome-based technological combination single product represent new generation modular therapeutic vaccine .</brief_summary>
	<brief_title>Phase I Hepatitis C Vaccine Trial Virosome-formulated Peptides</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy volunteer sex Aged 18 45 year Free obvious health problem With BMI 18.5 29.9 include give write informed consent Chronic acute illness Immunosuppression HCV and/or HBV infection history allergic disease Preexisting immune response peptide vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Liver disease</keyword>
	<keyword>Viral infection</keyword>
	<keyword>Virosome</keyword>
	<keyword>Vaccine</keyword>
	<keyword>therapeutic vaccine</keyword>
	<keyword>Chronic hepatitis C virus infection</keyword>
</DOC>